Evidence map›Paper›PMID 41559261›Full record

ArticleAnnals of hematology2026

Blinatumomab exposure prior to allogeneic stem cell transplantation is associated with increased Epstein-Barr virus reactivation.

Hai-Lu Sun, Zhi-Fan Zhao, Xian-Ying Yin, Meng Lv, Ling Ma, Fang-Fang Wei, Xiao-Su Zhao, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hai-Lu SunPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Zhi-Fan ZhaoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Xian-Ying YinPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Meng LvPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Ling MaPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Fang-Fang WeiPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Xiao-Su ZhaoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Yu WangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Lan-Ping XuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Xiao-Hui ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Xiao-Jun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Xu-Ying PeiPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, China. peixuying@pku.edu.cn.

Funding

Beijing Municipal Science & Technology Commission Z211100002921071Being Nova Program 20220484076Major Program of the National Natural Science Foundation of China 82293630Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0502400Peking University Medicine Fund for world's leading discipline or discipline cluster development 71003Y3035
6 · The paper itself

Abstract

Blinatumomab, a CD19/CD3 bispecific T-cell engager, is frequently used for B-cell acute lymphoblastic leukemia (B-ALL) prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although its efficacy in achieving measurable residual disease negativity is well established, its profound B-cell depletion and potential immunomodulatory effects may exacerbate post-transplant viral reactivation risks, particularly in the context of the inherent immunosuppression associated with allo-HSCT. In this matched retrospective cohort study, we identified 97 consecutive B-ALL patients who received blinatumomab prior to allo-HSCT between January 2021 and December 2024. Using 1:2 propensity score matching based on gender, age, and pre-transplant chemotherapy regimen, we selected 194 control patients from the same period who underwent allo-HSCT without prior blinatumomab exposure. Clinical outcomes were compared between the two cohorts. By day 100, EBV viremia incidence was significantly higher in the blinatumomab group (41.5% vs. 26.4%, p = 0.009), with blinatumomab identified as an independent risk factor (HR = 1.792, 95% CI 1.206–2.661, p = 0.004). Notably, immunoglobulin analysis revealed markedly lower IgA levels in the blinatumomab group (0.298 vs. 0.544 g/L, p < 0.001), while T-cell (CD3+/CD4+/CD8+) and B-cell (CD19+) reconstitution did not differ. One-year overall survival (OS) and non-relapse mortality (NRM) were also comparable. Blinatumomab exposure is associated with increased EBV reactivation post-allo-HSCT, likely linked to humoral immunity impairment. These findings underscore the need for enhanced EBV monitoring in this population after allo-HSCT.

Indexed as

Antibodies, BispecificEpstein-Barr Virus InfectionsHematopoietic Stem Cell TransplantationHerpesvirus 4, HumanVirus ActivationAdolescentAdultFemaleHumansMaleMiddle AgedPrecursor B-Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesTransplantation, HomologousYoung AdultAntibodies, BispecificblinatumomabAcute lymphoblastic leukemiaAllogeneic stem cell transplantationBlinatumomabEBV viremia

Identifiers

PMID41559261
PMCPMC12819470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.